. 2017 Jan 11;17(1):159–166. doi: 10.1007/s40268-016-0163-7

Table 5.

Net budgetary impact of ferric citrate vs. standard of care in two-way sensitivity analysis in which acquisition costs for ESA and IV iron are varied

Net budgetary impact of ferric citrate vs. SOC (US$/year per 100 patients treated)	Acquisition cost for ESA^a
	50% AWP (US$9.12/1000 U)	75% AWP (US$13.68/1000 U)	100% AWP (US$18.24/1000 U)
Acquisition cost for IV iron^a
50% AWP (US$4.32/100 mg)	+104,840	+157,138	+209,802
75% AWP (US$6.46/100 mg)	+106,946	+158,680	+210,447
100% AWP (US$8.64/100 mg)	+108,407	+160,399	+213,223

AWP average wholesale price, ESA erythropoiesis-stimulating agent, IV intravenous, SOC standard of care

^aBased on REDBOOK™ AWP; accessed 31 March, 2015